课题基金 / 基金详情

项目摘要

项目成果

Vesna Zderic的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本提案侧重于治疗性超声在改善眼部给药方面的应用。拟议的研究将解决一个重要的临床问题,因为通常很难在眼睛内的治疗部位达到药物的治疗水平。角膜是眼科药物的主要输送途径,具有生物屏障的作用,通常只有不到10%的药物能穿透眼睛前部,几乎没有渗透到眼睛后部。我们之前的研究表明,将兔角膜暴露在治疗性超声下,可以使一种模拟药物的化合物进入眼睛的量增加10倍,而角膜组织的变化很小。我们现在建议研究可以通过超声波增强给药来解决的临床相关问题,例如促进抗生素和抗炎药物的给药,以治疗眼部感染和炎症。我们的主要目标是找到能够提供临床相关的增强药物进入眼睛的超声参数,同时只在眼睛组织中产生轻微和可逆的变化。首先,我们建议建立一个理论模拟模型,该模型可以预测在不同参数(频率、强度、持续时间和占空比)下应用超声前后角膜药物(不同亲水性和分子大小)的通透性。然后,我们将开发用于药物输送的治疗性超声设备,这将允许完全控制不同的超声参数。这些装置将在体外和体内实验中进行测试。实验将利用白化兔的眼睛,白化兔是眼部给药的常用动物模型。超声应用于眼部药物输送的可行性将通过使用标准方法来测量暴露于超声或假处理(无超声应用)的穿过角膜的药物量来确定。治疗的安全性将通过在治疗后立即和治疗后14天内对超声引起的角膜结构和屏障特性变化进行眼科和组织学观察来确定。我们的长期目标是开发一种廉价、快速、微创的超声波给药方法,这种方法可以应用于门诊诊所或医院,使药物能够渗透到感染/炎症的眼部组织中,并在细菌、真菌或病毒造成永久性视力丧失之前,以足够的浓度给药,以对抗它们。
英文摘要
DESCRIPTION (provided by applicant): This proposal focuses on the application of therapeutic ultrasound in improving ocular drug delivery. The proposed research will address an important clinical problem since it is often difficult to achieve therapeutic levels of drugs at the treatment sites inside the eye. Cornea, which is a dominant route for delivery of ophthalmic drugs, acts as a biological barrier and usually less than 10% of the applied drug can penetrate into the front of the eye with virtually no penetration into the back of the eye. We have previously shown that exposing rabbit cornea to therapeutic ultrasound can lead to up to 10 times more delivery of a drug-mimicking compound into the eye, with only minimal changes in the corneal tissues. We are now proposing to work on clinically relevant problems that can be addressed with ultrasound-enhanced drug delivery, such as promoting delivery of antibiotics and anti-inflammatory drugs for treatment of eye infections and inflammations. Our main objective is to find ultrasound parameters that can provide clinically relevant enhancement of the delivery of medications into the eye, while producing only minor and reversible changes in the eye tissues. First, we are proposing to work on the development of a theoretical simulation model which can predict the permeability of the cornea for ocular medications (of different hydrophilicity and molecular size), before and after application of ultrasound at various parameters (frequency, intensity, duration, and duty cycle). We will then develop therapeutic ultrasound devices for drug delivery that will allow complete control of different ultrasound parameters. These devices will be tested in in-vitro and in-vivo experiments. The experiments will utilize eyes of albino rabbits, which are a usual animal model for ocular drug delivery. Feasibility of ultrasound application in ocular drug delivery will be determined by using standard methods for measurement of the amounts of drug that crosses the cornea which is exposed to ultrasound or sham-treated (no ultrasound application). Safety of the treatment will be determined by using ophthalmic and histological observations of ultrasound-induced changes in the corneal structure and barrier properties, immediately after the treatment and up to 14 days after the treatment. Our long-term goal is to develop an inexpensive, fast and minimally-invasive ultrasound method for drug delivery that can be applied in an outpatient clinic or in the hospital to allow medications to penetrate into eye tissues with infection/inflammation and deliver the drugs at a sufficient concentration to fight bacteria, fungi or viruses before they produce a permanent loss in vision. Public Health Relevance: Major eye infections/inflammations often result in the loss of vision due to corneal scarring. We believe that therapeutic ultrasound can offer an inexpensive and relatively simple method for improved delivery of medications into the eye. This method may allow faster treatment of corneal infections/inflammations as compared to currently used methods, thus potentially preventing permanent damage of the eye tissues.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1186/2050-5736-2-6
发表时间: 2014
期刊: Journal of therapeutic ultrasound
影响因子: --
作者: [Nabili M, Shenoy A, Chawla S, Mahesh S, Liu J, Geist C, Zderic V]
通讯作者: Zderic V
DOI: 10.1016/j.ultrasmedbio.2017.01.013
发表时间: 2017-06
期刊: Ultrasound in medicine & biology
影响因子: 2.9
作者: [Hariharan P, Nabili M, Guan A, Zderic V, Myers M]
通讯作者: Myers M
Therapeutic ultrasound for treatment of hypothyroidism
  • 批准号:
    10349615
  • 项目类别:
  • 资助金额:
    $8.08万
  • 财政年份:
    2022
  • 负责人:
    Vesna Zderic
  • 依托单位:
Therapeutic ultrasound for treatment of hypothyroidism
  • 批准号:
    10551996
  • 项目类别:
  • 资助金额:
    $8.08万
  • 财政年份:
    2022
  • 负责人:
    Vesna Zderic
  • 依托单位:
Therapeutic ultrasound for stimulation of insulin release
  • 批准号:
    10624803
  • 项目类别:
  • 资助金额:
    $49.11万
  • 财政年份:
    2020
  • 负责人:
    Vesna Zderic
  • 依托单位:
Therapeutic ultrasound for stimulation of insulin release
  • 批准号:
    10249079
  • 项目类别:
  • 资助金额:
    $48.14万
  • 财政年份:
    2020
  • 负责人:
    Vesna Zderic
  • 依托单位:
海外基金